FibroBiologics has completed manufacturing of the third batch of CYWC628 drug product for its ongoing Phase 1/2 clinical...
REPROCELL has submitted an application for manufacturing and marketing approval in Japan for Stemchymal, a regenerative ...
UniXell Biotechnology has received U.S. FDA Investigational New Drug clearance for UX-DA003, its allogeneic induced plur...
Ollin Biosciences has completed an oversubscribed US$330 million Series B financing to advance global Phase III developm...
Phanes Therapeutics has completed enrolment in its Phase II study of spevatamig in combination with standard-of-care che...
As artificial intelligence reshapes the future of genomic medicine, WhiteLab Genomics is positioning itself at t...
Cancer drug discovery is entering a more disciplined era. Investors, partners, and clinicians are increasingly focused o...
Cancer immunotherapy is entering a new phase—one that extends beyond targeting individual tumour cells and towards...
As biologics and cell and gene therapies continue to advance, manufacturing infrastructure is emerging as a critical det...
Sonire Therapeutics has received approximately $13 million in non-dilutive funding through Japan’s NEDO Deep-Tech ...
The Tang Prize Foundation has awarded the 2026 Tang Prize in Biopharmaceutical Science to three pioneers of cellular imm...
StemSight, a Finnish biotechnology startup developing off-the-shelf regenerative cell therapies for curing blindness, ha...
Neurocrine Biosciences has presented the first retrospective case series of CRENESSITY in patients with classic congenit...
Lundbeck has presented preliminary Phase II Part A data for asedebart, an investigational anti-adrenocorticotropic hormo...
CARsgen Therapeutics has presented new clinical data for two allogeneic CAR-T cell therapy candidates, CT0596 and CT1190...
In a landmark achievement in biological imaging, researchers at Biohub and the University of California, Berkeley today ...
Sanofi has received European Commission approval for subcutaneous Sarclisa, or isatuximab, in combination with standard-...
MEDIPOST has secured FDA agreement to conduct a single pivotal Phase III study for CARTISTEM in the US, marking an impor...
Regenerative medicine is steadily redefining the future of cardiovascular care, with cell based therapies moving beyond ...
Cell and gene therapies have demonstrated remarkable clinical potential, but translating scientific breakthroughs into w...
As cell and gene therapies transition from clinical development to commercial reality, the industry's attention is incre...
Researchers at King Abdullah University of Science and Technology (KAUST), Saudi Arabia, have developed a new method to ...
Miracell, a South Korea-based stem cell technology company, has obtained US FDA 510(k) clearance for its stem cell extra...
Matricelf, a biotechnology startup based in Israel developing a novel autologous engineered neural tissue therapy for pa...
Achondroplasia, the most common form of genetic dwarfism, has historically relied on treatment approaches that require f...
